IMDX · Company research
Insight Molecular Diagnostics Inc. Common Stock (IMDX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Mayo Clinic and Cleveland Clinic are among centers involved in a kidney test's FDA submission - Stock Titan | Mayo Clinic and Cleveland Clinic are among centers involved in a kidney test's FDA submission Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| A kidney transplant researcher will discuss how blood tests could help tailor anti-rejection care - Stock Titan | A kidney transplant researcher will discuss how blood tests could help tailor anti-rejection care Stock Titan | View source ↗ | Stock Titan | Oct 12, 2026 | neutral | 0 | 0.6 |
| Insight Molecular Diagnostics Inc (IMDX-Q) Stock Price and News - The Globe and Mail | Insight Molecular Diagnostics Inc (IMDX-Q) Stock Price and News The Globe and Mail | View source ↗ | The Globe and Mail | Oct 3, 2026 | neutral | 0 | 0.6 |
| $IMDX stock is down 15% today. Here's what we see in our data. - Quiver Quantitative | $IMDX stock is down 15% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 28, 2026 | neutral | 0 | 0.6 |
| Insight Molecular Diagnostics Inc. (IMDX) Slips 1.94% to $4.04 as Key Support Holds - Volatility Breakout Picks - https://www.siam.in/ | Insight Molecular Diagnostics Inc. (IMDX) Slips 1.94% to $4.04 as Key Support Holds - Volatility Breakout Picks https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Sep 4, 2026 | neutral | 0 | 0.6 |
| iMDx executives are set to meet investors in New York - Stock Titan | iMDx executives are set to meet investors in New York Stock Titan | View source ↗ | Stock Titan | Sep 2, 2026 | neutral | 0 | 0.6 |
| IMDX Initiated by Lucid Capital Markets -- Price Target Set at $8.00 - GuruFocus | IMDX Initiated by Lucid Capital Markets -- Price Target Set at $8.00 GuruFocus | View source ↗ | GuruFocus | Aug 24, 2026 | neutral | 0 | 0.6 |
| Insight Molecular Diagnostics (IMDX) Surges 16.4% as Diagnostics Sector Enthusiasm Grows - Extension Target - www.dars.gov.et | Insight Molecular Diagnostics (IMDX) Surges 16.4% as Diagnostics Sector Enthusiasm Grows - Extension Target www.dars.gov.et | View source ↗ | www.dars.gov.et | Aug 14, 2026 | neutral | 0 | 0.6 |
| New Medicare policy allows more donor-DNA tests after transplants - Stock Titan | New Medicare policy allows more donor-DNA tests after transplants Stock Titan | View source ↗ | Stock Titan | Jul 16, 2026 | neutral | 0 | 0.6 |
| IMDX Forecast — Price Target — Prediction for 2027 - TradingView | IMDX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment - Yahoo Finance | Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment Yahoo Finance | View source ↗ | Yahoo Finance | Jun 19, 2026 | neutral | 0 | 0.6 |
| Insight Molecular Diagnostics Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:IMDX) 2026-05-17 - Seeking Alpha | Insight Molecular Diagnostics Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:IMDX) 2026-05-17 Seeking Alpha | View source ↗ | Seeking Alpha | May 17, 2026 | neutral | 0 | 0.6 |
| Broadwood Partners, Neal C. Bradsher buy $2.03m of Insight Molecular Diagnostics - Investing.com India | Broadwood Partners, Neal C. Bradsher buy $2.03m of Insight Molecular Diagnostics Investing.com India | View source ↗ | Investing.com India | Apr 28, 2026 | neutral | 0 | 0.6 |
| Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst - Yahoo Finance | Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst Yahoo Finance | View source ↗ | Yahoo Finance | Apr 13, 2026 | neutral | 0 | 0.6 |
| How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst - Yahoo Finance | How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst Yahoo Finance | View source ↗ | Yahoo Finance | Mar 29, 2026 | neutral | 0 | 0.6 |
| iMDx Stock Rebounds After-Hours As Study Shows Transplant Test Works As Well As Market Standard - Stocktwits | iMDx Stock Rebounds After-Hours As Study Shows Transplant Test Works As Well As Market Standard Stocktwits | View source ↗ | Stocktwits | Mar 5, 2026 | neutral | 0 | 0.6 |
| iMDx Announces $26.0 Million Registered Direct Offering - GlobeNewswire | iMDx Announces $26.0 Million Registered Direct Offering GlobeNewswire | View source ↗ | GlobeNewswire | Feb 11, 2026 | neutral | 0 | 0.6 |
| Oncocyte (IMDX) Stock Price, News & Analysis - MarketBeat | Oncocyte (IMDX) Stock Price, News & Analysis MarketBeat | View source ↗ | MarketBeat | Nov 23, 2025 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Jun 20, 2025 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.